OS THERAPIES INCORPORATED Stock Price, News & Analysis

OS Therapies (NYSE-A: OSTX) has announced the formation of a new subsidiary, OS Drug Conjugates (OSDC), alongside strategic initiatives to leverage its patented silicone dioxide-based, pH-sensitive tunable antibody drug conjugates (tADC) and drug conjugates (tDC) platforms. The company is pursuing discussions with clinical-stage ADC therapeutics companies across the U.S. and China to establish joint ventures, with plans to spin these JVs into standalone public companies.

The company's proprietary technology utilizes SiLinkers™, pH-sensitive silicon-based linkers that connect targeting antibodies with therapeutic agents. This system is designed to release therapeutic agents specifically within tumors and their microenvironment, where pH levels are lower, maximizing treatment effectiveness while reducing harm to healthy cells.

According to BCC Research, the global antibody-drug conjugates market is projected to grow from $10.8 billion in 2023 to $47.0 billion by 2029, representing a CAGR of 28.4%.

OS Therapies (NYSE-A: OSTX) received a USPTO Notice of Allowance for a patent covering OST-HER2 commercial manufacturing methods, with market exclusivity extended into 2040. The company is preparing for FDA discussions following its Phase 2b clinical trial in osteosarcoma, aiming for BLA submission and potential FDA approval in 2025.

The company completed a $7.1 million financing in January 2025, providing capital into mid-2026. OST-HER2 holds rare pediatric disease, fast-track, and orphan drug designations. Phase 1 trials in HER2-expressing cancers showed promising results, including a 78% reduction in tumor size in breast cancer models and 65% reduction in metastatic cells.

The company targets the osteosarcoma market, estimated at $1.2 billion in 2022, with an expected $500 million opportunity for OST-HER2. The breast cancer market, valued at $29.2 billion in 2023, presents an additional $1 billion opportunity.

OS Therapies (NYSE-A: OSTX) has announced steps toward commercial manufacturing of OST-HER2, marking progress in its development of cancer immunotherapies. The company has secured agreements for commercial manufacturing as it prepares for a potential Biologics Licensing Authorization (BLA) submission to the FDA.

The announcement follows the completion of a Phase 2b trial testing OST-HER2 for preventing lung metastatic osteosarcoma recurrence. The company is currently organizing trial data for an upcoming Type B or Type C meeting with the FDA, after which it plans to submit a BLA application for accelerated or conditional approval consideration.

OS Therapies (NYSE-A: OSTX) provided a corporate update highlighting significant developments. The company completed a $7.1M financing round in January 2025, following a $6M IPO in August 2024, securing funding through mid-2026. Their Phase 2b trial of OST-HER2 for osteosarcoma met its primary endpoint with 33% responder rate vs 20% in control group, showing improved survival rates at 12 and 24 months.

The company acquired assets from Ayala, reducing future milestone payments and royalty rates from 10% to 1.5%. This acquisition includes rights to two Listeria-based immunotherapy candidates for lung and prostate cancer. OS Therapies is targeting FDA approval by late 2025, which could qualify for a Priority Review Voucher worth approximately $150M in non-dilutive capital.

OS Therapies (NYSE-A: OSTX) has entered into an asset purchase agreement to acquire listeria monocytogenes-based immuno-oncology programs and IP assets from Ayala Pharmaceuticals. The acquisition includes a Phase 2 lung cancer and Phase 1 prostate cancer program, along with direct ownership of IP related to OST-HER2 for osteosarcoma.

The deal, valued at $0.5 million in cash and $7.5 million in OSTX shares, eliminates milestone payments and reduces royalty obligations for OST-HER2. The company recently secured $7.1 million in financing at $4.00 per share, providing cash runway into 2026. The monthly burn rate is approximately $0.4M.

OS Therapies plans to request BLA for OST-HER2 in osteosarcoma in Q2 2025, with potential approval and Priority Review Voucher by end of 2025. The company is prohibited from issuing shares for 6 months and suspended equity line usage below $12.00 per share.

OS Therapies (NYSE-A: OSTX) has entered an asset purchase agreement to acquire listeria monocytogenes-based immuno-oncology programs and IP assets from Ayala Pharmaceuticals. The acquisition includes a Phase 2 lung cancer and Phase 1 prostate cancer program, along with direct ownership of IP related to OST-HER2 for osteosarcoma.

The deal involves a $0.5 million cash payment and $7.5 million in OSTX common shares. The company recently secured $7.1 million in financing at $4.00 per share, providing cash runway into 2026. OS Therapies plans to request BLA for OST-HER2 in osteosarcoma in Q2 2025, with potential FDA approval and Priority Review Voucher by end of 2025.

The agreement eliminates milestone payment obligations and reduces royalty rates for OST-HER2. The company's current burn rate is approximately $0.4M monthly, and they are prohibited from issuing shares for capital raising for 6 months and below $12.00 per share.

OS Therapies (NYSE-A: OSTX) announced positive results from its Phase 2b clinical trial of OST-HER2, showing statistically significant outcomes in treating recurrent, fully resected, lung metastatic osteosarcoma. The trial achieved its primary endpoint with 33.3% event-free survival (EFS) at 12 months compared to 20% historical control (p=0.0158).

The study demonstrated promising interim results for overall survival (OS), with 91% one-year survival and 61% two-year survival rates, compared to historical controls of 80% and 40% respectively. All patients achieving 12-month EFS remain alive in follow-up. The trial included 39 evaluable patients aged 12-39 years across 21 centers, with treatment consisting of 16 doses over 48 weeks.

Post-hoc analyses revealed higher EFS rates in females (47%) compared to males (20%), and better outcomes in patients with multiple prior lung resections (55%) versus single resection (25%). The treatment demonstrated a favorable safety profile in this population with no currently approved therapies.

OS Therapies (NYSE-A: OSTX) announced its CEO Paul Romness will attend the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco from January 13-16, 2025. Following their 2024 IPO and completion of Phase 2b clinical trial for OST-HER2 in treating recurrent, resected metastatic Osteosarcoma, the company plans to release trial data updates during the conference week.

The company anticipates potential FDA approval in 2025, which could earn them a Priority Review Voucher (PRV) valued at approximately $150 million. This voucher could be sold to fund OST-HER2's development for other HER2-positive cancers like Breast and Colorectal cancer. Despite recent changes in PRV program reauthorization, OS Therapies remains eligible for the voucher due to receiving rare pediatric disease designation before December 20, 2024, with approval targeted before September 30, 2026.

OS Therapies (NYSE-A: OSTX) has closed a $6 million private placement financing, with 98% of investment coming from Pre-IPO and/or IPO investors. The company sold 1.5 million units at $4.00 per unit, each consisting of one share of Series A Senior Convertible Preferred Stock and one warrant to purchase common stock at $4.40.

The funding is expected to provide cash runway into 2026, primarily supporting clinical and regulatory milestones for OST-HER2, their lead therapeutic candidate for recurrent, resected metastatic osteosarcoma. The company aims for commercialization in 2025 and remains eligible for a Priority Review Voucher (PRV), currently valued at approximately $150 million, which could fund expansion into other HER2 positive cancers.